Stable cell models are foundational tools for functional genomics, disease-mechanism research, and cell-therapy development. Researchers comparing variants of the same gene or testing multiple candidates in a shared genetic background often need more than a single clone: they need an expandable model system with a consistent genomic context and comparable expression levels.

Conventional integration strategies face several recurring constraints. Random integration can create position effects, clone-to-clone expression variability, and silencing during passaging. HDR-mediated knock-in generally becomes less efficient as cargo size increases and is strongly influenced by the locus, cell type, donor format, and delivery method. Viral vectors also impose payload and manufacturing constraints: AAV has a small effective packaging capacity, while lentiviral vectors can carry larger inserts but remain limited for very large payloads, multi-gene circuits, and precise copy-number control. Repeating sgRNA design and monoclonal screening for every new construct further slows iterative model development.

The LandingPad™ platform addresses these challenges through a two-step strategy: first establish a defined landing site, then install an attB-bearing cargo with Bxb1 recombinase. After integration, a single attP site is converted into attL and attR and is not simply reused for another cargo. The reusable asset is the validated master landing-pad cell bank, from which multiple derivative cell lines carrying different payloads can be generated in parallel.

LandingPad™ is based on the Bxb1 large serine recombinase, which recognizes the short attachment sites attP and attB and catalyzes directional recombination between them.

Step 1: Build an attP Landing-Pad Cell Line

CRISPR-mediated targeted knock-in is used to install attP at a commonly used safe-harbor locus such as AAVS1 or at a specified therapeutically relevant locus such as TRAC. Depending on the locus, cell type, and donor design, the project may use Flash-KI™ or another precision-editing strategy to support landing-site installation. After monoclonal screening, junction PCR, and sequence validation, the resulting attP cell line can be cryopreserved and maintained as a reusable master cell bank. Learn more about the Flash-KI™ platform.

Step 2: Integrate the Target Cargo

An attB-bearing donor and Bxb1 recombinase are introduced into the attP landing-pad cells. Recombination inserts the cargo at the predefined genomic site and generates attL and attR. In the absence of a recombination directionality factor, Bxb1 alone does not efficiently reverse this reaction, supporting stable maintenance of the integrated payload.

Core Design Rule: Genomic attP and Donor attB

Published work indicates that installing attB in the genome can permit unintended integration at genomic sequences with high attB similarity for wild-type and some evolved or engineered Bxb1 variants. In the same study, genomic attP configurations showed minimal off-target integration by ddPCR. A genomic attP plus donor attB configuration is therefore the preferred starting design, while project-specific off-target and copy-number testing should still be considered.

1. Landing-Site Selection

Common safe-harbor loci such as AAVS1 have substantial engineering precedent, but the insertion orientation, regulatory elements, cell background, and local transcriptional effects still require validation. Therapeutically relevant loci such as TRAC can place a payload within a specific endogenous regulatory context, although the resulting expression pattern depends on the cassette and locus design.

2. Donor Design

An attB donor may contain the payload, promoter, selection marker, and other regulatory elements. For multi-gene circuits, multiple transcription units can be assembled in one donor, or the host can be engineered with multiple or orthogonal landing sites. Because an occupied attP site cannot directly accept another cargo, the required number and combination of landing sites should be defined before construction. Insulators or anti-silencing elements may also be evaluated.

3. Delivery Strategy

Delivery should be selected according to cell type, donor size, and the chosen Bxb1 format, which may include plasmid, mRNA, protein, or an appropriate viral vector. Hard-to-transfect cells, primary cells, and iPSCs generally require pilot optimization to balance entry efficiency, transient expression, viability, and donor integrity. Where appropriate, EDITGENE can assess whether the FLASH delivery system is suitable for co-delivering CRISPR components and donor DNA.

4. Comparison with Flp-In and Cre-loxP

Table 1. Comparison of Three Site-Specific Integration Systems

1. Isogenic Stable-Expression and Overexpression Models

Installing all constructs at the same prevalidated site reduces position effects and background differences between clones. This approach is useful for isogenic variant panels, parallel expression of paralogs, reporter models, and inducible expression systems.

2. Large-Gene and Large-Cargo Disease Models

Bxb1 systems have supported targeted integration of cargoes larger than 10 kb in published studies. This makes landing-pad strategies worth evaluating for genes with large coding sequences, including DMD, BRCA2, and ATM. Feasibility still depends on donor production, delivery, locus selection, and cellular tolerance. Stepwise multi-component engineering requires multiple or orthogonal landing sites designed in advance.

3. Reporter Systems, Gene Circuits, and Synthetic Biology

Landing-pad systems allow different payload versions to be compared at the same validated genomic location, helping reduce host-background effects. Multi-landing-pad CHO systems have been reported to integrate approximately 100 kb of heterologous DNA across 21 transcriptional units with expression maintained for weeks. This result reflects a specific multi-site CHO engineering system and should not be interpreted as a universal capacity for one attP site or every cell type.

4. Engineered Cell Models for Cell-Therapy Research

Targeted installation of a properly designed CAR cassette at loci such as TRAC may improve expression consistency and place the construct within a defined endogenous regulatory context. Combinations of CARs, cytokine armoring, and safety switches can be explored through multi-transcription-unit donors or multi-landing-site strategies. Primary T-cell and iPSC projects also require evaluation of viability, phenotype, copy number, and functional safety.

1. Failure to Establish the attP Landing Site

When initial attP installation is inefficient, the guide and target site, donor format and homology arms, delivery parameters, and enrichment strategy can be optimized. HDR modulation or precision-editing-assisted installation may be evaluated according to cell state. High-fidelity Cas9 primarily reduces unintended cleavage; it does not directly guarantee higher HDR efficiency.

2. Low Integration Efficiency or Unintended Integration

Integration efficiency depends on the landing site, cell type, delivery method, donor size, and recombinase variant. In a published PASSIGE study, evolved or engineered Bxb1 variants reached up to approximately 60% integration for a specific donor in human cell lines with preinstalled landing sites, while eeBxb1 averaged about 23% targeted integration across multiple loci in single-transfection experiments. These are study-specific results rather than guaranteed project values. A genomic attP plus donor attB configuration reduces known attB-homology-related risks, but junction, copy-number, and unintended-integration assays may still be needed.

3. Transgene Silencing

Expression may decline during long-term passaging in some clones. Selecting a suitable locus, evaluating anti-silencing elements, and testing expression stability over serial passages can reduce this risk.

4. Inability to Add Another Cargo or Unexpected Cargo Loss

Bxb1 converts attP and attB into attL and attR, which are not efficiently reversed by Bxb1 alone without an RDF. This supports stability but does not mean drug selection is never required during construction. Selection depends on initial integration efficiency, donor design, and the intended deliverable. Additional or orthogonal landing sites must be reserved if further cargoes will be added to the same cell.

Random integration or conventional HDR may be sufficient for a simple, one-time stable-expression project. A landing-pad strategy becomes more attractive when researchers need to compare multiple variants in a shared genetic background, integrate cargoes larger than approximately 5 kb, build multi-gene circuits with defined architecture, reuse a validated master cell bank, or iteratively engineer payload combinations for cell-therapy research.

The value of a landing-pad system depends not only on Bxb1 itself, but also on coordinated landing-site installation, donor engineering, delivery, clone screening, and functional validation. EDITGENE can combine Flash-KI™ targeted knock-in, precision-editing, FLASH delivery, and monoclonal screening capabilities for LandingPad™ projects. The final strategy is evaluated according to the locus, cargo size, cell type, and required deliverable.

Stage 1: Establish the attP Landing-Pad Cell Line

The project may include feasibility assessment and attP installation at AAVS1, TRAC, or another specified locus, followed by junction PCR, sequencing, and copy-number analysis where required. The deliverable is a cryopreservable attP master cell line and validation report. A typical reference timeline is 8-12 weeks, depending on cell growth, installation efficiency, and validation scope.

Stage 2: Integrate the Target Cargo

EDITGENE can design and build the attB donor and select a suitable plasmid, mRNA, or protein format for Bxb1. Pool-level integration and junction accuracy may be assessed by flow cytometry, PCR, ddPCR, or sequencing. Initial pool analysis may be performed approximately 1-2 weeks after delivery, while monoclonal screening, expansion, and genotype validation require additional time. Homozygous integration depends on landing-site copy number and project design and is not a universal outcome.

Potential Deliverables

Deliverables may include the attP landing-pad cell line, attB donor vector or long DNA donor, a suitable Bxb1 component, integration-efficiency and junction-validation reports, and optional monoclonal sequencing, copy-number, or functional validation reports. The exact materials and assays should be confirmed during project scoping.

For teams seeking to build an expandable landing-pad cell bank or a targeted large-cargo cell model, EDITGENE can support feasibility assessment, donor design, pool analysis, monoclonal screening, and functional validation. Learn more about the Knock-In Cell Line service.